


White Paper:
White Paper: 4 Steps for Managing Biopharmaceutical Projects
The global biopharmaceutical market is expected to grow at a compound annual growth rate (CAGR) of 9.4% from 2014 to 2020, reaching $278 billion in revenue by the end of this six-year period. Growth is being driven by numerous factors: such as aging populations in most of the Western world and an increased prevalence of chronic disease. However, likely the most important contributor to growth is biopharmaceutical drugs’ superior effectiveness in treating many disease states, including treating conditions for which there were previously few effective drug treatment options available.
Given the growth of the biopharmaceutical segment, and biopharmaceuticals’ ability to more precisely treat many disease states, the industry needs to become increasingly better at managing biopharmaceutical projects in order for more treatment options to become available to patient populations.
The objective of any project management pursuit is to complete the project on time, within budget and within required quality or performance parameters. Whether making an automobile, computer or pharmaceutical, project management is not easy. However, given the complexity and intense regulatory demands of the pharmaceutical industry, project management is more difficult than many other segments. As if pharmaceutical projects weren’t demanding enough, biopharmaceutical project management is exceptionally challenging, requiring unique experience and expertise.
Download the Whitepaper
Complete the form below to download your copy!
You might also be interested in…
Navigating the European Union’s (EU) Drug Device Combination Product Regulatory Changes
White Paper: Navigating the European Union’s (EU) Drug Device Combination Product Regulatory ChangesThe European therapeutics market has been working to manage the upheaval caused by Brexit and is now working its way through yet another challenge: the medical devices...
Process Validation for Expedited Approval Drugs
White Paper: Process Validation and Regulatory Review in the Age of Expedited Approval Drugs Expedited approval drugs have profoundly changed the thinking and approach to Process Validation and other CMC activities. When working on the development of an expedited...
Cell Therapies – Overcoming Challenges Within the Regulatory Framework
White Paper: Cell Therapies Come of Age: Overcoming Challenges Within the Regulatory FrameworkWithin the cell therapy arena, regulators, the medical community and industry alike are often confronted with an unsettling question. What is this, really? Should a given...